Ack1: Activation and Regulation by Allostery

The non-receptor tyrosine kinase Ack1 belongs to a unique multi-domain protein kinase family, Ack. Ack is the only family of SH3 domain containing kinases to have an SH3 domain following the kinase domain; others have their SH3 domains preceding the kinase domain. Previous reports have suggested that Ack1 does not require phosphorylation for activation and the enzyme activity of the isolated kinase domain is low relative to other kinases. It has been shown to dimerize in the cellular environment, which augments its enzyme activity. The molecular mechanism of activation, however, remains unknown. Here we present structural and biochemical data on Ack1 kinase domain, and kinase domain+SH3 domain that suggest that Ack1 in its monomeric state is autoinhibited, like EGFR and CDK. The activation of the kinase domain may require N-lobe mediated symmetric dimerization, which may be facilitated by the N-terminal SAM domain. Results presented here show that SH3 domain, unlike in Src family tyrosine kinases, does not directly control the activation state of the enzyme. Instead we speculate that the SH3 domain may play a regulatory role by facilitating binding of the MIG6 homologous region to the kinase domain. We postulate that features of Ack1 activation and regulation parallel those of receptor tyrosine kinase EGFR with some interesting differences.

[1]  John Kuriyan,et al.  Regulation of the catalytic activity of the EGF receptor. , 2011, Current opinion in structural biology.

[2]  E. Manser,et al.  The Cdc42-associated kinase ACK1 is not autoinhibited but requires Src for activation. , 2011, The Biochemical journal.

[3]  W. Miller,et al.  Regulation of Ack-Family Nonreceptor Tyrosine Kinases , 2011, Journal of signal transduction.

[4]  W. Miller,et al.  Regulation of Ack1 localization and activity by the amino-terminal SAM domain , 2010, BMC Biochemistry.

[5]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.

[6]  Xiaolin Hao,et al.  Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[7]  G. Carpenter,et al.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.

[8]  Ron Bose,et al.  Inhibition of the EGF Receptor by Binding to an Activating Kinase Domain Interface , 2007, Nature.

[9]  J. Mohler,et al.  Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.

[10]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[11]  J. Schlessinger,et al.  Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[13]  Ole Kristensen,et al.  A unique set of SH3–SH3 interactions controls IB1 homodimerization , 2006, The EMBO journal.

[14]  W. Miller,et al.  Phosphorylation of WASP by the Cdc42-associated Kinase ACK1 , 2005, Journal of Biological Chemistry.

[15]  James L Mohler,et al.  Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. , 2005, Cancer research.

[16]  S. Powers,et al.  Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Lim,et al.  SNX9 as an adaptor for linking synaptojanin‐1 to the Cdc42 effector ACK1 , 2005, FEBS letters.

[18]  M. Dagher,et al.  Effects of p47phox C Terminus Phosphorylations on Binding Interactions with p40phox and p67phox , 2005, Journal of Biological Chemistry.

[19]  P. Mak,et al.  Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the Cdc42-associated Tyrosine Kinase ACK1* , 2004, Journal of Biological Chemistry.

[20]  W. Miller,et al.  Biochemical Properties of the Cdc42-associated Tyrosine Kinase ACK1 , 2003, Journal of Biological Chemistry.

[21]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[22]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[23]  L. Lim,et al.  Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas , 1999, Nature Cell Biology.

[24]  P E Bourne,et al.  Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. , 1998, Protein engineering.

[25]  J. Kuriyan,et al.  Structures of Src-family tyrosine kinases. , 1997, Current opinion in structural biology.

[26]  John Kuriyan,et al.  Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.

[27]  J. Kuriyan,et al.  Activation of the Sire-family tyrosine kinase Hck by SH3 domain displacement , 1997, Nature.

[28]  Michael J. Eck,et al.  Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.

[29]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[30]  Wendell A. Lim,et al.  Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains , 1995, Nature.

[31]  L. Lim,et al.  A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42 , 1993, Nature.

[32]  Andrea Musacchio,et al.  Crystal structure of a Src-homology 3 (SH3) domain , 1992, Nature.

[33]  K. Terpe.  Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems , 2002, Applied Microbiology and Biotechnology.

[34]  R. Armstrong,et al.  Structure, catalytic mechanism, and evolution of the glutathione transferases. , 1997, Chemical research in toxicology.

[35]  Wenqing,et al.  Three-dimensional structure of the tyrosine kinase cSrc , 2022 .